• BridgeBio Pharma published a medical research presentation analyzing serum transthyretin variability in ATTR-CM patients from ATTRibute-CM.
• Landmark analysis linked lower intraindividual sTTR variability (population median CVi 7.94%) with lower all-cause mortality, independent of mean achieved sTTR (full model HR 0.56; 95% CI 0.35-0.89; p=0.014).
• Higher mean achieved sTTR was also independently associated with lower all-cause mortality (full model HR 0.46; 95% CI 0.24-0.85; p=0.014).
• Acoramidis 800 mg BID reduced sTTR variability versus placebo from Day 28 through Month 30 (p<0.001), with variability reduction accounting for 20% of the drug’s effect on all-cause mortality.
• Acoramidis arm more consistently maintained sTTR above thresholds through Month 12, including 25 mg/dL in 77% of patients versus 28% on placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.